Bayer receives Japanese approval for finerenone to treat patients with chronic heart failure: Berlin Tuesday, December 23, 2025, 14:00 Hrs [IST] Bayer announced that Japan’s Min ...

An ongoing trial at the Medical University of South Carolina is looking for a breakthrough for patients dealing with heart ...

Dr Pradeep highlights warning signs of heart failure, including increased urination at night, swollen ankles, and breathlessness.

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

Cytokinetics announced FDA approval of MYQORZO™ (aficamten) to treat adults with symptomatic obstructive hypertrophic ...

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...

The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and ...

Martha Gulati, MD, explains how bias and underrepresentation in research lead to misdiagnosis of HFpEF in women and delays in ...

Aficamten, a first-in-class cardiac myosin inhibitor, offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed ...

Patients with elevated epicardial adipose tissue volume (EATV) exhibit greater acute myocardial injury following acute ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...